BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 31752756)

  • 1. Preoperative risk stratification for early recurrence of HBV-related hepatocellular carcinoma after deceased donor liver transplantation: a five-eight model development and validation.
    Al-Ameri AAM; Wei X; Lin L; Shao Z; Guo H; Xie H; Zhou L; Zheng S; Xu X
    BMC Cancer; 2019 Nov; 19(1):1136. PubMed ID: 31752756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Early Recurrence of Hepatocellular Carcinoma in Patients with Cirrhosis Who Had Received Deceased Donor Liver Transplantation: A Multicenter Study.
    Al-Ameri AAM; Wei X; Liu P; Lin L; Shao Z; Xie H; Zhou L; Zheng S; Xu X
    Ann Transplant; 2019 Aug; 24():489-498. PubMed ID: 31427563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience.
    Varona MA; Soriano A; Aguirre-Jaime A; Garrido S; Oton E; Diaz D; Portero J; Bravo P; Barrera MA; Perera A
    Transplant Proc; 2015; 47(1):84-9. PubMed ID: 25645778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B and hepatocellular carcinoma recurrence after living donor liver transplantation: The role of the Milan criteria.
    Vatansever S; Farajov R; Yılmaz HC; Zeytunlu M; Paköz ZB; Kılıç M
    Turk J Gastroenterol; 2019 Jan; 30(1):75-80. PubMed ID: 30644364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histological differentiation predicts post-liver transplantation survival time.
    Li WX; Li Z; Gao PJ; Gao J; Zhu JY
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):201-8. PubMed ID: 24388339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Matching Status Between Donor and Recipient Hepatitis B Seroepidemiology Makes a Difference in Liver Transplantation for Hepatocellular Carcinoma.
    Lu D; Yang F; Zhuo J; Yang M; Lin Z; Jin P; Cai X; Cen B; Wang J; Wei X; Zheng S; Xu X
    Clin Transl Gastroenterol; 2020 May; 11(5):e00168. PubMed ID: 32358239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes mellitus may affect the long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after liver transplantation.
    Zhang Q; Deng YL; Liu C; Huang LH; Shang L; Chen XG; Wang LT; Du JZ; Wang Y; Wang PX; Zhang H; Shen ZY
    World J Gastroenterol; 2016 Nov; 22(43):9571-9585. PubMed ID: 27920478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of survival and tumor recurrence rates in patients undergoing liver transplantation for hepatitis B-related hepatocellular carcinoma using Milan, Shanghai Fudan and Hangzhou criteria.
    Gao T; Xia Q; Qiu DK; Feng YY; Chi JC; Wang SY; Xi ZF; Zhang JJ; Xu N; Chen SY; Qiu YL; Shen LW; Zhou TT; Dong XJ; Li QG; Li H
    J Dig Dis; 2013 Oct; 14(10):552-8. PubMed ID: 23782458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Hangzhou criteria with neutrophil-lymphocyte ratio is superior to other criteria in selecting liver transplantation candidates with HBV-related hepatocellular carcinoma.
    Xiao GQ; Yang JY; Yan LN
    Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):588-95. PubMed ID: 26663006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
    Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
    Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative Alfa-Fetoprotein and Fibrinogen Predict Hepatocellular Carcinoma Recurrence After Liver Transplantation Regardless of the Milan Criteria: Model Development with External Validation.
    Jiang N; Zeng KN; Dou KF; Lv Y; Zhou J; Li HB; Tang JX; Li JJ; Wang GY; Yi SH; Yi HM; Li H; Chen GH; Yang Y
    Cell Physiol Biochem; 2018; 48(1):317-327. PubMed ID: 30016765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation.
    Hong G; Suh KS; Suh SW; Yoo T; Kim H; Park MS; Choi Y; Paeng JC; Yi NJ; Lee KW
    J Hepatol; 2016 Apr; 64(4):852-9. PubMed ID: 26658686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences.
    Zheng SS; Xu X; Wu J; Chen J; Wang WL; Zhang M; Liang TB; Wu LM
    Transplantation; 2008 Jun; 85(12):1726-32. PubMed ID: 18580463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
    Mehta N; Heimbach J; Harnois DM; Sapisochin G; Dodge JL; Lee D; Burns JM; Sanchez W; Greig PD; Grant DR; Roberts JP; Yao FY
    JAMA Oncol; 2017 Apr; 3(4):493-500. PubMed ID: 27838698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center.
    Franssen B; Alshebeeb K; Tabrizian P; Marti J; Pierobon ES; Lubezky N; Roayaie S; Florman S; Schwartz ME
    Ann Surg; 2014 Oct; 260(4):650-6; discussion 656-8. PubMed ID: 25203882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
    Mazzaferro V; Sposito C; Zhou J; Pinna AD; De Carlis L; Fan J; Cescon M; Di Sandro S; Yi-Feng H; Lauterio A; Bongini M; Cucchetti A
    Gastroenterology; 2018 Jan; 154(1):128-139. PubMed ID: 28989060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.